alpha-Dihydroartemisinin
Antimalarial Efficacy: Demonstrates potent activity against asexual-stage Plasmodium parasites, including chloroquine-resistant and piperaquine-resistant strains of falciparum malaria.
Oral Bioavailability: Exhibits excellent gastrointestinal absorption, with maximum plasma concentrations attained within 1.33 hours following oral administration.
Clinical Validation: Employed for treating all malaria types, particularly in critical presentations such as cerebral malaria and severe drug-resistant variants.
Safety Profile: Maintains a favorable toxicological profile without teratogenic effects, as confirmed through gestational administration in animal models.
Dihydroartemisinin demonstrates strong efficacy against asexual erythrocytic stage Plasmodium parasites, effectively managing clinical symptoms and clearing various Plasmodium species during their asexual reproductive cycles. It maintains activity against both chloroquine-resistant and piperaquine-resistant strains of falciparum malaria while presenting an advantageous safety profile. Animal reproductive studies indicate that gestational exposure in murine models may elevate fetal resorption rates, though no teratogenic effects were documented.
Parameters
Melting point | 142-144°C |
Boiling point | 375.6±42.0 °C(Predicted) |
density | 1.24±0.1 g/cm3(Predicted) |
storage temp. | 2-8°C |
solubility | Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) |
form | Solid |
pka | 12.61±0.70(Predicted) |
color | White to Off-White |
Safety Information | |
alpha-Dihydroartemisinin Usage And Synthesis | |
Chemical Properties | White needle like crystal |
Uses | antimalarial, antiinflammatory |
Definition | ChEBI: Dihydroartemisinin (DHA) is an artemisinin derivative. |
target | Antifection |
This antimalarial agent achieves excellent oral bioavailability, reaching peak plasma concentrations (Cmax) of 0.71 μg/ml within 1.33 hours (tmax) following oral administration at 2 mg/kg dosage. The compound is clinically indicated for all malaria variants, proving particularly valuable in emergency management of cerebral malaria and severe cases involving chloroquine- or piperaquine-resistant falciparum malaria.
